MARKSANSNSEMarksans Pharma Limited· Pharmaceuticals & BiotechnologyHighPositive
Announced Wed, 8 Jul, 2026 · 10:13 IST

Marksans Pharma to acquire 100 percent stake in Germany's ABCnow GmbH

Listed Co AcquisitionStrategic Transactions View source PDFExplain this filing

MARKSANS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+0.8%Reaction day
₹261.80
prior close
₹266.40
announcement price
In-mkt
timing
Nifty Microcap 250market-2.0%+2.8% vs market
Pharmaceuticals peers, median of 165sector-0.8%+1.6% vs sector

On the reaction day the stock moved 2.8 pts more than Nifty Microcap 250 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.7
10m
+0.8
15m
+0.9
30m
+1.1
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+0.8-2.0+2.8-0.8+1.6
Next day
+6.5-0.1+6.6+0.0+6.5
2d
+3.8+1.2+2.6+0.5+3.3
3d
+3.1+1.4+1.7+1.0+2.1
4d
+3.5+0.4+3.2+0.2+3.3
5d
+5.5+1.0+4.5+0.8+4.6
1w
+1.8-0.5+2.3-0.4+2.2
15d
-0.9-0.6-0.4-0.3-0.6
1m
+3.7+3.4+0.3-0.3+4.0
2m
+28.0+6.0+21.9+3.1+24.9
3m
+17.6+1.1+16.6-1.7+19.4
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Marksans Pharma has signed a definitive agreement to acquire 100% of German pharma distributor ABCnow GmbH for about EUR 892,384 in cash. ABCnow markets OTC products in Germany with revenue of EUR 227,234 in 2025 and EUR 510,216 in 2024. The deal is not a related party transaction, needs no regulatory approval, and is expected to close by July 31, 2026. The acquisition gives Marksans a direct front-end to sell its products manufactured in India, UK and USA across the EU market.

Likely market impact

Expands Marksans Pharma's direct owned presence in European markets through German sales and distribution, supporting long-term EU growth.